Table 6 Comparisons of clinical, laboratory and pathological data in patients with lower plasma CFH level group
From: Clinical relevance of glomerular IgM deposition in patients with lupus nephritis
Lower plasma CFH level group | |||
|---|---|---|---|
IgM 3+–4+ N = 30 | IgM 0–2+ N = 135 | P | |
Clinical evaluation | |||
Gender (male %) | 6 (20.0%) | 17 (12.6%) | 0.380 |
Age (mean ± s.d.) (years) | 31.1 ± 10.5 | 33.3 ± 11.8 | 0.411 |
SLEDAI (mean ± s.d.) | 17.2 ± 5.2 | 18.0 ± 5.8 | 0.408 |
Laboratory assessment | |||
Hemoglobin (mean ± s.d.) (g/L) | 100.9 ± 26.5 | 99.6 ± 25.7 | 0.859 |
Urine protein (median; IQR) (g/24 h) | 5.7 ± 3.1 | 4.6 ± 3.3 | 0.026 |
Scr (mean ± s.d.) (μmol/L) | 150.1 ± 121.0 | 124.7 ± 140.6 | 0.015 |
Plasma C1q (mean ± s.d.) (μg/mL) | 33.2 ± 18.8 | 33.2 ± 18.8 | 0.191 |
Plasma C3 levels (mean ± s.d.) (g/L) | 0.30 ± 0.2 | 0.44 ± 0.22 | 0.023 |
Plasma C4 levels (mean ± s.d.) (g/L) | 0.23 ± 0.17 | 0.21 ± 0.18 | 0.756 |
Plasma CFH levels (mean ± s.d.) (μg/mL) | 294.6 ± 131.1 | 338.7 ± 124.3 | 0.052 |
Plasma soluble C5b-9 levels (mean ± s.d.) (ng/mL) | 1225.9 ± 571.2 | 1271.4 ± 657.8 | 0.785 |
Pathological parameters | |||
AI (median; IQR) | 8 (6, 10) | 8 (4, 11) | 0.695 |
Endocapillary hypercellularity | 3 (2, 3) | 3 (1, 3) | 0.620 |
Cellular crescents | 0 (0, 2) | 0 (0, 2) | 0.591 |
Karyorrhexis/fibrinoid necrosis | 0 (0, 2) | 0 (0, 2) | 0.640 |
Subendothelial hyaline deposits | 1 (1, 3) | 1 (0, 2) | 0.118 |
Interstitial inflammatory cell infiltration | 1 (1, 1) | 1 (1, 2) | 0.856 |
Glomerular leukocyte infiltration | 1 (1, 1) | 1 (0, 1) | 0.454 |
CI (median; IQR) | 2.5 (2, 4) | 2 (2, 4) | 0.368 |
Glomerular sclerosis | 0 (0, 1) | 0 (0, 1) | 0.970 |
Fibrous crescents | 0 (0, 1) | 0 (0, 0) | 0.228 |
Tubular atrophy | 1 (1, 1) | 1 (1, 1) | 0.481 |
Interstitial fibrosis | 1 (1, 1) | 1 (1, 1) | 0.604 |